Drugs in Dev. Immunology
Phase I/ Phase II
Denmark 
Lead Product(s) : Arachis Hypogaea Allergen Extract
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Positive Results Advance Peanut Tablet to Phase II Development
Details : ALK Abello AS is developing sublingual immunotherapy (‘SLIT’) tablets and it is under phase 1/2 clinical development for the treatment of Peanut Allergy.
Product Name : Peanut SLIT-tablet
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 18, 2024
Lead Product(s) : Arachis Hypogaea Allergen Extract
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NMD670
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NMD670, a small molecule inhibitor of skeletal muscle-specific ClC-1, Administration of single doses of NMD670 was associated with clinically significant improvements in Quantitative Myasthenia Gravis Score with up to 50% of patients meeting pre-specifie...
Product Name : NMD670
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : NMD670
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NMD670
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Jeito Capital
Deal Size : $39.6 million
Deal Type : Financing
NMD Pharma Raises €35 Million in a New Financing
Details : Proceeds from the financing will be used to support the company as it progresses its lead candidate, NMD670, through completion of the ongoing Phase 2a proof-of-concept trial in patients with Myasthenia Gravis (MG).
Product Name : NMD670
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 15, 2022
Lead Product(s) : NMD670
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Jeito Capital
Deal Size : $39.6 million
Deal Type : Financing
Lead Product(s) : NMD670
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NMD670 is in development to treat the symptoms of MG and is also being evaluated for the treatment of other neuromuscular diseases.
Product Name : NMD670
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 30, 2021
Lead Product(s) : NMD670
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NMD670
Therapeutic Area : Immunology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : NMD670 is a first-in-class small molecule inhibitor of the muscle specific chloride ion channel, the ClC-1 ion channel.
Product Name : NMD670
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 10, 2020
Lead Product(s) : NMD670
Therapeutic Area : Immunology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
